Lowering effect of valsartan on fetuin-A in type 1 diabetes mellitus.
BACKGROUND
Fetuin-A (A2-HS-glycoprotein) is a protein that plays several functions in human physiology and pathophysiology. The role of fetuin-A in type 1 diabetes mellitus (DM) has been less studied. We investigated the serum levels of fetuin-A in type 1 diabetic patients with microalbuminuria. Furthermore, the blocking effect of renin-angiotensin-aldosteron system on serum levels of fetuin-A was assessed.


METHODS
From January 2010 to May 2011, 32 patients with type 1 DM with confirmed microalbuminuria were included in this study in Isfahan, Iran. Serum fetuin-A levels before and 8 weeks after valsartan administration were measured. In addition, serum lipid profile, creatinine, hemoglobin A1c, and urine microalbuminuria were determined.


RESULTS
The mean age of participants was 21.65 +/- 0.38 years. Before valsartan administration, the mean values of fetuin-A were not significantly different between males and females (64.22 +/- 1.77 ng/mL versus 61.39 +/- 3.35 ng/mL, respectively). After valsartan administration, serum levels of fetuin-A and urine albumin-creatinine significantly decreased. A negative correlation was observed between serum fetuin-A level after valsartan administration and serum low-density lipoprotein cholesterol level (P = .007, r = -0.507).


CONCLUSIONS
Administration angiotensin receptor blockers concomitantly decreases fetuin-A levels and urine albumin levels.
Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. sh_haghjoo@med.mui.ac.ir.
Alaleh
A
Gheissari
Shaghayegh Haghjooye
SH
Javanmard
Rooholah
R
Shirzadi
Masood
M
Amini
Nooshin
N
Khalili
D000328:Adult; D000419:Albuminuria / Q000150:complications / Q000378:metabolism*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D008078:Cholesterol, LDL / Q000097:blood; D003401:Creatine / Q000652:urine; D003430:Cross-Sectional Studies; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000378:metabolism*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D013777:Tetrazoles / Q000494:pharmacology*; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan; D055815:Young Adult; D060749:alpha-2-HS-Glycoprotein / Q000187:drug effects / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D008078:Cholesterol, LDL; D003401:Creatine; D006442:Glycated Hemoglobin; D013777:Tetrazoles; D014633:Valine; D000068756:Valsartan; D060749:alpha-2-HS-Glycoprotein; C517652:hemoglobin A1c protein, human